tpr-met, a tyrosine kinase oncogene, is the activated form of the met proto-oncogene that encodes the receptor for hepatocyte growth factor/scatter factor. The tpr-met product (p65tP`-t) was tested for its ability to induce meiotic maturation in Xenopus oocytes. While src and abl tyrosine kinase oncogene products have previously been shown to be inactive in this assay, p65tPr-met efficiently induced maturation-promoting factor (MPF) activation and germinal vesicle breakdown (GVBD) together with the associated increase in ribosomal S6 subunit phosphorylation. tpr-met-mediated MPF activation and GVBD was dependent on the endogenous c_mos,e, while the increase in S6 protein phosphorylation was not significantly affected by the loss of mos function. The phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine inhibits tpr-met-mediated GVBD at concentrations that prevent insulin-but not progesterone-induced oocyte maturation. Moreover, maturation triggered by tpr-met is also inhibited by cyclic AMP-dependent protein kinase. This is the first demonstration that a tyrosine kinase oncogene product, p6V5t-met, can induce meiotic maturation in Xenopus oocytes and activate MPF through a mos-dependent pathway, possibly the insulin or insulinlike growth factor 1 pathway.The c-met proto-oncogene product has recently been identified as the hepatocyte growth factor/scatter factor receptor (7,27). The met proto-oncogene was discovered via the activated oncogene, tpr-met (46), that was generated in a human osteogenic cell line treated with N-methyl-N-nitro-N-nitrosoguanidine (11). Activation resulted from a DNA rearrangement between the tpr sequence from chromosome 1 and downstream met tyrosine kinase receptor sequences located on chromosome 7 (28, 46). The tpr-met product, 5tPr-me6 , induces transformation of NIH 3T3 cells as a constitutively expressed tyrosine kinase (11).The Xenopus oocyte system is useful for examining the events involved in signal transduction (58). Fully grown Xenopus oocytes arrested at the G2/M border (40) can be induced to enter M phase by progesterone, insulin, or insulinlike growth factor 1 (IGF-1). A marked decrease in cyclic AMP (cAMP) levels is an early biochemical change that occurs in oocytes after progesterone treatment. This decrease is due to inhibition of adenylate cyclase (22,31,(49)(50)(51). In contrast, maturation induced by insulin and IGF-1 involves inhibition of adenylate cyclase as well as stimulation of a phosphodiesterase activity (52, 53). The hormones initiate the activation of maturation-promoting factor (MPF), germinal vesicle breakdown (GVBD), chromosome condensation, completion of meiosis I, and progression to metaphase arrest at meiosis II. MPF is a cytoplasmic protein kinase activity that participates in GVBD as well as chromosome condensation (38, 42) and consists of the homologs for the major cell cycle oscillator p34cdc2 and B-type cyclins (15,17,24,25,41,47). The mos proto-oncogene product is required for both progesterone-and insulin-induced oocyte maturation and therefore...